🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 426897104 (prev. 21234W103 )
- Market Cap
- Micro Cap
- Previous Symbol
- CTRV (changed 7/22/2019)
- Previous Name
- ContraVir Pharmaceuticals, Inc.
Business: Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Notes: July 22, 2019 -- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that its Board of Directors has approved the change of the Company’s name and stock symbol to Hepion Pharmaceuticals, Inc. and “HEPA,” respectively. The Company’s new NASDAQ trading symbol will be effective as of the opening of trading on July 23, 2019, as will a new CUSIP number for the Company’s common stock of 426897104.
Company Contact
- CEO
- Robert Foster
- CFO
- John Cavan
- Headquarters
- 399 Thornall Street, First Floor, Edison, NJ 08837
- Phone
- 732-902-4000
- Fax
- 732-902-4100
- Investor Relations
- Stephen Kilmer · 646-274-3580 · skilmer@hepionpharma.com